Related Experiment Videos
Reduced bone mineral density in HIV-positive individuals
A L Moore1, A Vashisht, C A Sabin
1Centre for HIV Medicine, Royal Free Hospital, London, UK.
AIDS (London, England)
|September 8, 2001
Summary
Reduced bone mineral density (BMD) affects 71% of HIV-positive patients, particularly those treated with protease inhibitors (PI). This finding impacts decisions on initiating HIV treatment and selecting therapeutic agents.
Area of Science:
- Medical Research
- Bone Health
- Infectious Diseases
Background:
- Human Immunodeficiency Virus (HIV) infection is associated with various comorbidities.
- Bone mineral density (BMD) loss is a recognized complication in HIV-positive individuals.
- The role of specific antiretroviral therapies in bone health remains an area of active investigation.
Purpose of the Study:
- To assess the prevalence of reduced bone mineral density (BMD) in a cohort of HIV-positive patients.
- To investigate potential associations between reduced BMD and prior treatment with protease inhibitors (PI).
Main Methods:
- A cohort of 105 HIV-positive patients was evaluated.
- Dual-energy X-ray absorptiometry (DEXA) scans were utilized to measure bone mineral density (BMD).
- Patient treatment histories, including protease inhibitor (PI) use, were reviewed.
Main Results:
- A high prevalence of reduced BMD was observed in 71% of the studied HIV-positive patients.
- Patients with a history of protease inhibitor (PI) treatment exhibited a higher prevalence of reduced BMD.
- These findings suggest a potential link between PI therapy and diminished bone mineral density.
Conclusions:
- Reduced bone mineral density is highly prevalent in HIV-positive individuals.
- Protease inhibitors (PIs) may be associated with an increased risk of reduced BMD.
- The study contributes to the ongoing discussion regarding optimal timing and agent selection for HIV treatment initiation.